The Value of OCT and OCTA as Potential Biomarkers for Preclinical Alzheimer’s Disease: A Review Study

Preclinical Alzheimer’s disease (AD) includes cognitively healthy subjects with at least one positive biomarker: reduction in cerebrospinal fluid Aβ(42) or visualization of cerebral amyloidosis by positron emission tomography imaging. The use of these biomarkers is expensive, invasive, and not alway...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Cuenca, Inés, Salobrar-García, Elena, Elvira-Hurtado, Lorena, Fernández-Albarral, José A., Sánchez-Puebla, Lidia, Salazar, Juan J., Ramírez, José M., Ramírez, Ana I., de Hoz, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306512/
https://www.ncbi.nlm.nih.gov/pubmed/34357083
http://dx.doi.org/10.3390/life11070712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306512/
https://www.ncbi.nlm.nih.gov/pubmed/34357083
http://dx.doi.org/10.3390/life11070712

Ejemplares similares